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Abstract
Policies and health actions generate benefits that extrapolate the specificity of its purpose of providing welfare for the population, given its
recognized impact in generating technological innovations, employment and income. However, such progress levels are unevenly distributed in
countries, so that certain diseases and allocative and ethical questions associated with the development of new mechanisms for diagnosis, of
treatment and cure did not find satisfactory answers yet. In Brazil, such a scenario has not been shown different, demanding a wider discussion
encompassing the country’s economic and social conditions. Contrasting the analytical and empirical results observed in policies and actions toward
the Health Economic-Industrial Complex (CEIS) to establish the barriers as well as structural and economic opportunities for the promotion of
health innovations in Brazil, this work raises a number of critical considerations in view of identifying and systematizing gaps in health innovation
in the country, thereby proposing a positive comprehensive research agenda on the topic.
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Introduction
In the last decade, Brazil developed some guidelines aiming at
strengthening the national system for the promotion of Science,
Technology and Innovation (S,T&I) in health. As a highlight,
we mention the advent of the Sectoral Funds in 1999; of the
Industrial, Technological and Foreign Trade Policy (PITCE) in
2003; the Productive Development Plan (PDP) in 2008; the
Greater Brazil Plan (PBM) in 2011; the National Strategy for
Science, Technology and Innovation (ENCTI) of the Ministry
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of Science, Technology and Innovation (MCTI) from 2012 to
2015 and, more recently, from 2016 to 2019. In addition to
these policy actions, some others are being established as a
way to strengthen innovation and technology development in
the health segment, such as the creation of the Executive Group
of the Health Industrial Complex (GECIS) in 2007, the CT-
Health Fund and the National S,T&I Policy for Health in 2004
and the Program for the Development of the Health Industrial
Complex (PROCIS) in 2012. In this work we mention the names
of the programs in English but maintain their original Brazilian
Portuguese acronyms.
In Brazil, persist a lack of coherent and functional health poli-
cies that include a more effective participation of universities and
firms in the creation and transformation processes of knowl-
edge into internationally competitive innovations. This aspect
obfuscates the gains achieved so far (Viana & Elias, 2007). This
point is still featured in the document of the “ENCTI from 2016
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to 2019” of the MCTI (Ministry of Science, Technology and
Innovation, 2015), which shows the high Brazilian dependence
on foreign technologies and innovations in health care. This is a
clear justification for highlighting the need for a research agenda
in the area of health innovations in Brazil.
These aspects influence the Brazilian development agenda,
giving rise to concerns on what increases the vulnerability of
the national health system, bringing to light the need to deepen
the scientific knowledge based on the subject. Despite the insti-
tutional gains achieved when comparing the current situation
with that of two decades ago (Marques, 1999), a challenge
that persists remains overcoming the fragile national production
structure, with an emphasis on both health products and the med-
ical supplies sides (Gadelha, Vargas, Maldonado, & Barbosa,
2013). Other aspects are added, such as the reorientation of tech-
nological innovations, a structural link in public policy, and the
establishment of the collective welfare of the country (Gadelha,
Costa, & Bahia, 2015).
The Brazilian government has a significant role in the devel-
opment of a socially and economically important production
base to increase the technological density of the Economic
Industrial Health Complex (CEIS). According to Gadelha
(2003), the CEIS is a structural link that involves not only social
demands for goods and services in health, but also a techno-
logically competitive production base. It consists of dynamic
and systemic secondary links that, although quite different from
each other, share the same political and institutional frameworks.
Thus, the action of the Brazilian government is potentially induc-
ing the dynamics of a dense and complex production chain
as the CEIS because of the centrality of government in the
procurement of goods and services and in inducing regional
policies in health services (Bahia, Costa, Gadelha, & Vargas,
2015).
There is therefore the need for a wide-ranging discussion
about the difficulties of communication and consolidation of
CEIS in light of specific characteristics, economic and social
conditions and the corporate and government dynamics. Thus,
contrasting the analytical and empirical results, this paper aims
to highlight the health innovation gaps in Brazil and raise a set of
concerns around three central axes toward the composition of a
research agenda on health innovations in Brazil. The intention is
to place the barriers and structural/conjectural opportunities for
the support of health innovation in Brazil. It is worth mentioning
that the issues and considerations raised no claim of complete-
ness of the theme, as the focus of this work is to contribute to
a broader debate on this subject, which we believe is important
to the development of Brazil and other developing countries in
similar conditions.
This paper is divided into six sections, including this intro-
duction. Section 2 discusses the concept of Health Innovation
System (HIS), rescuing a number of recent considerations of
the literature on the evolution of HIS, highlighting its implica-
tions for Brazil. Section 3 provides an overview of challenges
and international efforts in health S,T&I. Section 4 presents the
methodological aspects of the research. Section 5 contextualizes
and discusses health innovation gaps in Brazil. Finally, Section
6 elaborates the final considerations.
Health Innovation Systems (HIS): a review of literature
The stylized dynamics of a Health Innovation System (HIS)
stems from the widespread knowledge available in the litera-
ture on innovation systems (IS). A HIS is a system driven by
endogenous and localized interactions between various units,
such as the ecology of agents and their connections, by coordina-
tion mechanisms brought by the institutional environment, and
by the growing interdependencies between domains (Orsenigo,
Dosi, & Mazzucato, 2006). Different aspects such as scien-
tific research, regulation, patient care and market processes
are translated to these domains, whereby innovations are non-
deterministic and emergent processes (Bloom & Wolcott, 2013).
The role of social technologies is also important, as well as
the institutional propagators along the coordination processes
that facilitate the implementation of scientific and technologi-
cal advances within the clinical activity in medicine (Consoli
& Mina, 2009). Having said that, a HIS characterizes a rich
ecosystem formed by individuals, institutions and organizations
whose interactions aim to contribute over time to the emergence
of coherent paths of technological change. Such environments
emphasize the collective nature and long-term innovation pro-
cesses and their dependence on generated feedback mechanisms
during the delivery process of medical innovations to society,
without, however, skew the incentive systems that move the
different subsystems.
Therefore, an HIS encompasses a broad sphere of medical
technologies and clinical services, such as new drugs, devices
and medical practices that occur in the context of social tech-
nologies and institutional structures, which in turn generate the
conditions for both release and dissemination. As a result, the
attention of public policy must be given not only to the develop-
ment of intermediate goods for the provision of health services,
but also for organizational and institutional settings that support
the development and introduction of new medical technologies
(Gadelha et al., 2013).
The greatest challenge of our time for the consolidation of a
HIS is in the design of more appropriate interpretative models of
the diffusion and utilization processes of medical technologies.
However, an extensive literature states that use and development
of technologies are variables that go together in an innovation
process that mutually shapes one another throughout a learning
process, which, in turn, expands or reduces the scope for the
application of the technology (Bloom & Wolcott, 2013; Gelijns
& Rosenberg, 1994). The greatest difficulty, however, is in the
set of assumptions that support each interpretative model.
For example, Consoli and Mina (2009) discuss the role of
hospital managers, patients, insurers and regulators in the rate
of diffusion and direction of medical innovations throughout
the importance of these actors in the explicit identification of
priorities and in the redefinition of modes of functioning and
funding strategies that stimulate the emergence and spread of
new technologies. Consoli and Mina (2009) argue that studies
on the roles users in the adoption of innovations in the medical
field are treated as static components of their analysis.
On the other hand, approaches more typically framed in the
fields of sociology and health policies see the incorporation of
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medical technologies as a result of a process of change in time,
which involve considerations on the evolution of the mecha-
nisms by which the demand for new treatments and technologies
are established and financed. Innovation in health herein outlined
involves a variety of forms of knowledge whose evolutionary
paths are rooted in the contexts in which they emerge and
interact (Bloom & Wolcott, 2013). Such analytical consider-
ations emphasize the historical and institutional perspectives, as
well as technological dimensions outlined above. Therefore, a
proper understanding of how an HIS evolves in terms of its main
objectives comes from whether its development perspective is
geared toward a dynamic or a static framework, whereby, in each
case, institutional processes are compared with technological
processes (Consoli & Mina, 2009).
Consoli and Mina (2009) suggest HIS approaches to be seen
on a functional perspective. That is, development strategies
based on the optics of Health Innovation Systems should focus
on the aspects that originally initiate an Innovation System. This
means that the greatest wealth of the concepts and theories of
Innovation System is in its ability to emerge and develop in
response to specific problems whose solutions employ differ-
ent forms of expertise that depend on its coordination. In other
words, the contours of such systems suffer continuous evolution,
transcending sectoral or technical barriers. The most important
aspects of this process are all the changes in the institutional
structure, which gives supports to the IS.
Therefore, the IS approach aligns to both the overall medical
and clinical settings. On the one hand, the organization of health
services starts a wide range of activities involving technical skills
and practical knowledge, which require efficient coordination
mechanisms aimed to achieve certain standards of patient care
(Gadelha et al., 2013). On the other, the search for the implemen-
tation of new clinical solutions in the context of an IS directs the
redistribution of knowledge along the areas of expertise, giving
opportunities for new connections that, in its turn, lead to other
connections and so on (Bloom & Wolcott, 2013).
In this line of reasoning, the concept of CEIS is an inter-
pretative model of the operation of an HIS that starts from the
dynamic perspectives of relations, on both the institution and
the technology sides. In Box 1 we summarize the main actors
in a CEIS, as well as their roles in the process of generation,
dissemination and use of innovations in the healthcare industry.
Conceived as a link in the expansion of the operation of the
CEIS, Brazil’s National Health Plan from 2016 to 2019, or PNS
2016–2019, comes under the guidelines of the National Health
Council (CNS) to stimulate the expansion of domestic produc-
tion of strategic technologies in healthcare. Therefore, one of the
PNS’s objectives is to “promote the production and dissemina-
tion of scientific and technological knowledge, health situational
analysis, health innovations and the expansion of domestic pro-
duction of strategic technologies for the Unified Health System
(SUS)” (Ministry of Health, 2016, p. 69). Despite this focus,
both the PNS 2016–2019 and the ENCTI 2016–2019 do not
show, for example, a proposal for the configuration of an insti-
tutional framework encompassing actors, roles, responsibilities
and resources aimed at linking a process of diffusion and use of
medical technologies promoted by a national HIS or by many
regionalized HIS around specific themes, as well as the existing
or required resources to ensure its feasibility. In the attempt to
contribute to this debate on the need to expand the Brazilian HIS
that the next topics of this work are established. But before that,
we believe it is necessary to present a set of broader perspec-
tives on the matter, along with the current challenges for health
innovation.
Perspectives and challenges in health innovation
In order to face more emphatically the current worldwide
problems in health innovation, the OECD suggests that the atten-
tion of public policies and the interested society segments should
focus on three main aspects: (i) science and technology; (ii)
industrial organization; and (iii) financial barriers (Organization
for Economic Cooperation and Development, 2010).
The HIS is the process by which new drugs, vaccines and
diagnostics are produced and made available to its users. It is an
environment that has suffered from declining productivity, ris-
ing operating and research and development (R&D), and risks of
patents’ infringements in developing countries (Durand-Zaleski,
Chevreul, & Jeanblanc, 2009; Hyewon, 2014; Organization for
Economic Cooperation and Development, 2013; Stossel, 2015).
Still, failure and rejection rates remain high despite of the
promises brought by new technologies. It is possible that there
is a difficulty of pharmaceutical companies to properly address
the solutions to the different demands generated in the HIS,
reflecting to some extent in their market value, which has led
to a number of mergers, acquisitions and strategic alliances
worldwide (Davis & Abraham, 2013). Summarizing, there is
uncertainty about the future structure of the biopharmaceutical
industries and global biotechnology, creating challenges in their
management processes of knowledge, intellectual property and
innovation.
The structure of the biopharmaceutical industry is a hotly
debated topic. Some see the increased outsourcing of services
and knowledge management as a new production organization of
the pharmaceutical industry oriented to the formation of ecosys-
tems over global networks, outsourcing certain services, such as
R&D. It is a common reality in other sectors, such as semi-
conductors (Lange, Muller-Seitz, & Windeler, 2013). Others,
however, believe that the difficult capital investment decisions
and the complexity of the health sector indicate a return to a
more vertically integrated structure (Organization for Economic
Cooperation and Development, 2010).
The search for financing in the early stages of research, the
high development costs of products and government approvals,
financial pressures and their impact on the market value of
biotech and pharmaceutical companies, as well as restrictions on
the public purse has been a constant in the industry (Industrial
Research Institute, 2015; Stossel, 2015).
Therefore, in view of the challenges in science and technol-
ogy, in industry organization, and in the financial constraints (on
the public and private sides), the prospects of policies for densi-
fying production chains harboring different interests throughout
their nodes, even among those in the public sector, present chal-
lenges not only in the governance structure, but also on the
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Box 1: Main actors of a health innovation system
Actor Roles played in the process of creation and diffusion of innovations
Hospitals Hospitals are “loci” of clinical practice. That is, they are the main
channel that reveals potential new treatments, drawbacks and where
casual observations are made so that they can be key to the
development process of new ideas for treatments with existing
technologies.
Research institutions
(They include hospitals with research units,
research foundations or research institutes in
universities)
Act as medical educational institutions and are usually linked to
academic institutions. As such, on the one hand, they act as links in
the dissemination of knowledge, with special emphasis on the tacit
components in the processes of generation and dissemination of new
practices and medical knowledge.
Moreover, they also function as organizational links between the
experimental and basic phases of research (i.e., clinical trial). Yet, they
act as an important source of practical information for innovation in
medical devices and equipment. The role of users is fundamental, as
they are not only sources of information but well-informed actors on
the medical necessity to be treated and on the range of plausible
solutions.
Universities University units (pharmacology, biology, genetics, computer science,
engineering, etc.) complement the activities described above for
hospitals and research institutions.
Firms Companies are – in developed countries – the largest investors in
R&D in an industry where competition is more frequently induced and
motivated by innovations. Also, while the merits of the products of
discovery is often shared with universities, companies have
distinctive competencies in product development, management of
the regulatory process for approval of new drugs and devices, as well
as on marketing and distribution of medical innovations.
Governments Articulate public policies, regulations relating to phytosanitary and
public health in order to align institutional interests and promote the
welfare of the population.
Source: authors’ elaboration on Gadelha et al. (2013), Gelijns and Rosenberg (1994), Consoli and Mina (2009), and Mazzucato and Dosi
(2006).
outcomes expected by society. Health Innovation Systems in
industrialized economies are in transition, seeking more efficient
forms of productive and knowledge organization, as well as more
functional models for evaluating uncertain and long-term matu-
rity investments in knowledge intensive projects (Organization
for Economic Cooperation and Development, 2013). In a con-
text such as of Brazil, in which the problems and challenges
mentioned above coexist with the low national capacity to carry
out R&D and to produce innovations aligned with the national
picture of health and disease of the population, such problems
become of even greater dimensions.
Materials and methods
There is a significant number of researches by Brazilian
authors exploring the institutional links to the consolidation of
local innovation systems, the cultural and systemic determinants
of innovation among firms, as well as on the dynamics underpin-
ning university–industry cooperation for innovation and its role
in generating successful spin-offs (Botelho & Almeida, 2010;
Machado & Barzotto, 2014; Paranhos & Hasenclever, 2011;
Viana & Elias, 2007).
However, there is still little knowledge about how public
policy, in particular the S,T&I policies, influence business con-
ditions in general and, more specifically, the business models
and business strategies of firms, given the barriers and the very
dependence of Brazilian companies to public funding.
Given the limited availability of studies on this topic assessing
the context of Brazil and other developing countries, the authors
have adopted a “how” and “why” questioning perspective as
a theory-building approach (Yin, 2003). The research is there-
fore exploratory, as it directly responds to the need of building
the foundations of a theory exploring the relationship between
the gaps in health innovation in Brazil and the research agenda
required to analyze, propose and debate the amplified set of
actions required to overcome these gaps. Consequently, given
the exploratory nature of this research paper, we avoid generating
hypotheses to test relationships between variables (Edmondson
& McManus, 2007).
The first stage in this research consisted in the review of lit-
erature to present the state of the art in science, technology and
innovation in health. The second stage comprised documental
analysis involving the Brazilian health policies framework and
the situation of the domestic industry in health-related areas. The
analysis generated a process through which a company, public
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policy or sectoral context studied indicated further evidence of
government and business spheres to be analyzed. Because of
this process, two new documents released by the Brazilian Fed-
eral Government were included in the research for analysis: The
National Strategy for Science and Technology (ENCTI) from
2016 to 2019 and the National Health Plan (NHP) from 2016 to
2019. In this way, we believe we can contribute to a better under-
standing of the recent health S,T&I policy framework in Brazil,
as well as with a set of propositional issues related to a future
agenda for more comprehensive research on the theme, which
we deem necessary to reduce the gaps between innovation and
health in the country.
Data analysis had two purposes in this research. First, it
allowed the identification of the analytical framework within
which the authors highlighted the set of gaps for health inno-
vation. Second, it allowed for a more detailed understanding
of the current outlook of the Brazilian public policy, includ-
ing a systematization of the challenges ahead. The data were
crosschecked with information from public sources (press, com-
pany websites, scientific articles and consultancy reports), which
allowed the construction and the triangulation of evidence pro-
vided by the study.
The authors acknowledge that caution is required in making
generalizations based on the results of an exploratory research.
However, we expect that the exploratory nature of this study
will not invalidate its merit as an empirical research effort,
as it highlights the need for a clearer adherence of S,T&I
health policies with the national industrial and scientific struc-
tures. This approach is aligned with international best practices
in exploratory research employing surveys or case studies on
themes exploring how S,T&I policies evolve in response to
demands of society (Lange et al., 2013; Lehoux, Daudelin,
Williams-Jones, Denis, & Longo, 2014; Probert, Connel, &
Mina, 2013).
Still, the identification of the required constructs for the pro-
posal of a set of questions relevant for a research agenda that,
accompanied by an extrapolation in the final remarks and the
urgency in meeting these issues, proved to be a valid strategy
for exploring such a complex theme in a developing country
context. Similar approaches were presented in Parasuraman and
Grewal (2000) and Aguinis and Glavas (2012).
As a way to analyze the data, the authors set out the conceptual
framework of analysis carried out by the OECD (Organization
for Economic Cooperation and Development, 2010, 2013),
choosing to systematize the gaps in science and health tech-
nology in Brazil along in three main axes: (i) science and
technology; (ii) industrial organization; and (iii) financial bar-
riers. In each of these axes we present a set of propositional
questions aimed at stimulating an integrated research agenda
and a debate on health innovation in the context of a developing
country like Brazil. Next, we present and discuss the three axes
in the light of the recent Brazilian experience.
Gaps and challenges for Brazil
In view of various challenges to the consolidation of a
CEIS in the country, the Brazilian Innovation Agency (FINEP)
and the National Bank for Economic and Social Development
(BNDES), along with the Ministry of Health (MS), have pre-
sented a set of structured proposals to ensure a decentralized
development to the actions for Science, Technology and Innova-
tion in Brazil. Based on the structure presented by the documents
of the OECD (2010, 2013), we discuss the gaps and challenges
in Brazil in light of the Brazilian federal government action plans
envisaging more effective innovation health developments in the
country, as presented by both the ENCTI from 2016 to 2019 and
the PNS from 2016 to 2019.
Science & technology
One cannot consider the science and technology policy
framework in Brazil without mentioning the country’s Inno-
vation Law. With the entry of the Innovation Law (Law No.
10.973/2004) and its regulation through Decree No. 5,563 in
October 2005, Brazil started to have a new funding instrument
for innovation and scientific research and technology in the
national production environment. The Brazilian Innovation Law
aims to establish a set of mechanisms to facilitate the transfer of
researchers between the science and technology institutions and
business segments, with researchers working in the private sec-
tor without losing their formal link with their home institutions.
In addition, several of its main mechanisms and guidelines are
focused on the promotion and funding of university–industry
cooperation. Despite the huge challenges ahead, the Innovation
Law introduced in the country the notion that an important part
of the bottlenecks in university–industry cooperation is to reduce
institutional and legal barriers that prevented those actors who
have already envisioned university–industry cooperation as a
key link in the generation of high economic impact innovations.
However, after ten years of its enactment, the Innovation Law
has not proved as effective as expected. Some strategic sectors,
such as health technologies, biofuels, semiconductor and oil &
gas have not managed to take off, despite the framework enacted
for their development, even after the introduction of this Law
and other support mechanisms derived from the Law (Alves,
Quelhas, da Silva, & Lameira, 2015; Pinto & Feldmann, 2016;
Suzigan, Albuquerque, & Cario, 2011).
The purpose of the Innovation Law was to extend the
public–private partnership for innovation, but the interface
between the public and private sectors does not happen only
in the context of research networks, but also in the legal rela-
tionship between the parties. One of the recurring diagnosis is
that the bottleneck of this partnership would be mainly in the
public sector (Alves & Pimenta-Bueno, 2014; Suzigan et al.,
2011). It was in this context that the law authorized the cre-
ation of Special Purpose Companies (SPC) to develop projects
in partnership with private partners. These companies should
be subsidiaries of research institutions so that, in the future,
this should allow SCPs to count on the income generated by
this type of institutional innovation. There are, however, con-
cerns about the consistency of the Law. First, because it creates
some legal instruments for university–industry cooperation but
does not improve, for example, the flexibility and autonomy
of public institutions in managing their human and financial
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resources. Later, the Law devotes significant attention to the
commercialization efforts of the innovation, but not to the cre-
ation of research capacity within private enterprises (Botelho &
Almeida, 2010).
Until recently, the Brazilian Innovation Law lacked more
precise regulation regarding aspects such as the treatment
of intellectual property produced by university researchers
with companies, as well as the appropriate legal treatment to
researchers in the rigid statutory regime of federal public uni-
versities who are actively involved in private companies, among
other things. Resulting from an intense debate over the last
decade in Brazil, Law No. 13,243 of January 11, 2016, provides
new incentives to scientific and technological development,
research, and innovation for the country. This new Law emerged
in lieu of the 2004 Innovation Law. However, it is still early to
know if such aspects as listed above shall be indeed settled, since
many of these issues still need further specific regulations at the
federal level and, consequently, also in the state levels.
Yet, although a wider investigation of its determinants in the
country remains necessary, it is possible that the structure and
dynamics of health innovations in Brazil are being set out on
generally assumed foundations rather than thoroughly discussed
and analyzed with the actors and stakeholders involved. Inno-
vations in the biomedical and pharmaceutical fields depend on
the context in which they operate and should not occur isolated
from the characteristic framework underlying their socioeco-
nomic systems, which are necessary for the definition of their
organizational and market basis. For example, the case involving
the national mobilization around the epidemic potential of the
Zika virus required a broader national effort, with different forms
of expertise formed around a specific issue of potential socio-
economic consequences. Such problems do also occur in other
areas of the clinical practice and general health in Brazil, each
requiring different forms of coordination and resource mobi-
lization around the same functional structure at the national and
regional basis, as it should be the country’s CEIS.
Therefore, besides the challenges brought by the decline
in production and exports of two links of the Brazilian CEIS
(Chemical Industry and Biotechnology Base and Mechanical,
Electronics and Materials Industry Base), there is still another
challenge to be overcome by national health S,T&I policies.
Regarding the innovation process, in general, the pharmaceuti-
cal and national medical equipment industry also reveals a clear
detachment of the world’s technological frontier (Gadelha et al.,
2013). This is evident particularly in terms of the significant
gap between the national and international competitive stan-
dards in R&D efforts, especially in those segments with higher
technological density as biological drugs or biopharmaceuticals
(Federal Planning Bureau, 2013; Gadelha et al., 2015).
The considerations above result in the discussion made in
Brazil on the importance of coordination among institutional
actors along the CEIS to address the risks outlined (Gadelha
et al., 2013). Some researchers believe that the motivation of
these aspects is the relative neglect of the role played by the
service sector in innovation studies (Consoli & Mina, 2009),
therefore influencing how the articulation of public policies for
the Health Innovation System evolves and consolidates.
In face of what was earlier discussed, one of the goals in
the Ministry of Health’s PNS (2016, p. 69) is to “promote the
production and dissemination of scientific and technological
knowledge, health situational analysis, health innovation and the
production expansion of national strategic technologies for the
Unified Health System (SUS)”. The goals set out in the PNS aim
to meet a four-year planning horizon (2016–2019), thereby sug-
gesting the still low evolution of the health innovation process in
Brazil. To achieve these ends, the PNS presents a comprehensive
set of strategic goals (Ministry of Health, 2016, p. 70). The first
is to increase from 1 to 9 the number of technologies internal-
ized in the country’s Unified Health System (SUS), which will
be produced by the Partnerships for Productive Development
(PDP). Second, to promote scientific research, technology and
innovation aimed at improving the health condition of the pop-
ulation and to improve the mechanisms and management tools
for the regulation and health care in the SUS. Third, to develop
and/or absorb through the PDPs 8 new drugs.
These objectives and targets in the PNS show that little
progress has been made in recent years and that the problems
faced are still persisting in health innovation policies and actions.
The national effort is still shy, which implies the need for a
research agenda on the following questions:
• Assuming that the university-business cooperation presup-
poses very different organizational structures – depending
on the maturity of the relationship, on the objectives for the
cooperation, etc. – how to better encourage, in the context
of the targets, goals and strategies encompassed in the PNS
2016–2019, the university–industry cooperation for health
innovation?
• How to increase the flow of researchers, scientists and technol-
ogy and innovation managers of public and private institutions
in health and related areas, aiming at a better socioeconomic
exploitation of the knowledge shared that is useful for both
the public and the private parties?
• As globalization accelerates, and in face of the specificities
and disparities between Brazilian States, how to coherently
address the development of new platforms and technological
standards for the health of the population, with a view to a
necessary convergence of technologies in areas such as biol-
ogy, engineering, computer science, synthetic biology and
nanotechnology?
• With distinct and specific interests in multiple territories of the
country, the consolidation of local capacity to boost the poten-
tial for innovation involves ensuring access to multiple data
sources, domestic and foreign. Make these data sources inter-
operable in a continental country is a challenge that requires
more efficient use of sophisticated information and commu-
nication technologies to interconnect the resources and make
them more efficiently available to their users.
Industrial organization
The domestic market of medicines, drugs and adjuvants
changed substantially from 2010 onwards, with imports of
medicines ranking five times higher than the exports. For drugs
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and adjuvants, the scenario is even less favorable for Brazilian
exports in relation to imports. The main causes of such a perfor-
mance degradation, in the industry point of view, was attributed
to the federal and state tax structures and the detrimental pub-
lic oversight and regulatory barriers to domestic producers over
those of foreign origin (Brazilian Association of Pharmaceutical
Chemicals Industry and Pharmaceutical Supplies, 2014).
Despite the drop in exports of medicines and pharmaceutical
supplies, the scenario that prevailed until 2010 was of represen-
tative growth. Most likely, in addition to the structural issues
that affect the performance of the Brazilian industry, the unfa-
vorable international economic environment also contributed to
the drop in the performance of Brazilian exports of medicines
and pharmaceutical supplies. One of the elements that con-
tributed to the growth in production observed until 2010 – and
consequently of Brazilian exports – is the consolidation of the
‘generic’ medicines segment in the country, which represented
a turning point in the growth trajectory of the national pharma-
ceutical industry.
Still, despite the decline in exports from 2010 onwards,
imports of pharmaceutical drugs and supplies continue to grow
more than exports, especially from China (Brazilian Association
of Pharmaceutical Chemicals Industry and Pharmaceutical
Supplies, 2014). The fall in exports is a reflection of the overall
reduction in Brazilian industrial production since 2011. Also,
in 2012 the scenario for the medical equipment market – the
mechanical, electronic and materials base of the CEIS – has
also changed, reflecting the behavior of the national industry in
other sectors as well.
Still, the growth of domestic sales of supplies and equip-
ment for medical and diagnostic purposes has been supported
by increasing imports of equipment and raw materials rather than
by the domestic production in these segments. Apparently, the
increase in domestic sales, particularly of medicines, biophar-
maceuticals and medical and dental equipment, even in a still
adverse economic scenario shows that the CEIS services base
in the country continues to demand inputs and products that are
being gradually supplied by imports.
Possibly, the worst scenario for the country would be the
absence of the Partnerships for Productive Development (PDPs).
The PDPs allowed partnerships between public and private pro-
ducers for the production of drugs, vaccines, medical equipment
and devices for diagnosis. The public sector, particularly the
Ministry of Health, was the main client of the partnerships taking
place in the framework of the PDPs. Obviously, the fulfillment
of the expectations built around these actions will depend on the
continuity of long-term policies, the economic conditions, the
quality of funded projects and on the criteria for the selection
and establishment of partnerships. The PDP, through the exist-
ing legal framework, becomes viable by means of the public
procurement led by the Ministry of Health, which entails pref-
erence margins for the acquisition of domestic products and raw
materials.
The ‘Programa Inova Saúde’, or Health Innovate Program,
can also become an important partner in the consolidation of
these instruments. It is an initiative of the Ministry of Science,
Technology and Innovation (MCTI) along with the Brazilian
Innovation Agency (FINEP). This initiative occurs in coopera-
tion with the Ministry of Health (MS), the Brazilian Bank for
Economic and Social Development (BNDES) and the National
Scientific and Technological Development Council (CNPq)
to support Research, Development and Innovation (R,D&I)
projects from public and private institutions operating under the
CEIS. Launched in April 2013, it is still early to assess its effec-
tiveness. However, some aspects related to other initiatives in
Brazil and abroad can motivate the construction of an elaborate
set of contributions so that the Innovate Health Program can
increase its chances of achieving the objectives pursued by its
idealizers. The Health Innovate Program was quoted in ENCTI
document, noting that:
(. . .) the program achieved significant results in relation to its
main objective of creating the support and financing condi-
tions whose results can effectively contribute to the reduction
of the country’s technological dependence on the supply of
important inputs in the field of human health. The program is
inserted into the Innovate Enterprise Plan (Programa Inova
Empresa), which will allocate R$ 3.6 billion until December
2017 for supporting innovation activities of the Health Com-
plex. (Ministry of Science, Technology and Innovation, 2015,
p. 43).
Even with the argument that the program has reaped posi-
tive results, the only indication for the expansion of Innovate
Health Program is a possible investment of R$ 3.6 billion
by the end of 2017. It is still a timid investment compared
with other programs like Brazil’s Profarma, coordinated by the
BNDES.
The consolidation of the generic medicines policy has also
boosted the growth of the Brazilian pharmaceuticals market.
The BNDES’ Profarma was enacted in this context, when the
improvement of the pharmaceuticals value chain was defined
as a priority by the PITCE in 2004. The increase in production
capacity of the Brazilian pharmaceuticals and health equipment
industry, the need to adapt to international standards of pro-
duction, the expansion of innovation efforts and the need to
strengthen national companies were the main objectives defined
in the creation of Profarma. Having been redesigned in 2007
to increase the penetration of the CEIS into the national health
segments, Profarma focuses on the induction and support of
technological innovation projects, as well as to align the indus-
try agenda with the demands of the MS. In its third renewal,
active until 2017, Profarma expects to inject an additional R$ 5
billion in these initiatives.
A detailed assessment of the Profarma program involving
all its beneficiaries has not yet been performed. Therefore, it
is not yet possible to assess the extent of economic externali-
ties and social benefits produced such as skilled job creation by
the firms supported, impacts on the CEIS, patents derived by the
financed projects and the supported firms turning public through
Initial Public Offers and the like. A challenge for Profarma is
also to stimulate innovation in small businesses. According data
collected by the authors on the institutional websites of the part-
ners of the program, 3/4 of resources released benefited medium
and large companies. Small businesses often present difficulties
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in providing collaterals and to adhere to the strict terms of the
public calls (Alves & Pimenta-Bueno, 2014).
Still, a similar situation occurs in the nuclear technology
sector, which is strategic for health innovations. Despite the
observed improvements, nuclear technologies are underutilized
in the country, with relatively low investments in the public
sphere and practically none in the private, as noted by the
ENCTI document itself (Ministry of Science, Technology and
Innovation, 2015, p. 15).
The new possibilities for outsourcing R&D services in health,
as noted worldwide, are an important link to be captured by
national policies, since attracting foreign research labs can bring
positive externalities that contribute to the consolidation of the
CEIS. This aspect goes beyond the public policy framework
mentioned in previous lines, as it involves a more comprehensive
articulation with a myriad of actors aiming to design the most
appropriate set of incentives and protection measures to facilitate
the entry into the country of these global players.
Actions and national business strategies should therefore
focus on business models that allow business players to remain
economically viable in an environment of uncertainty and
increased competition with both industrialized and developing
economies. Each of the national CEIS segments demand detailed
assessments of new trends in the markets for raw materials, prod-
ucts, technologies and health services, especially public health,
requiring different strategies. These strategies should encom-
pass: (i) a solid schedule for private R&D going beyond the next
five years; (ii) an efficient management of intellectual property
and contracts in partnership with national and foreign entities for
the development of new products and services in health; and (iii)
marketing strategies that are successful for expanding domestic
products and services into new markets, particularly abroad.
Existing restrictions and constraints are a result of the
still modest incidence of innovations in Brazilian companies
(Botelho & Almeida, 2010; Pinto & Feldmann, 2016), as well as
the low launch of new products and services derived by the col-
laboration of firms with universities and research centers (Alves
& Pimenta-Bueno, 2014; Suzigan et al., 2011). Therefore, the
role of policy actions such as Innovate Health, Profarma, the
PDPs and sector funds (see next section) may be an important
link for the solution of these bottlenecks in the coming decades.
However, without economic policies that reduce the risks for
private investment in the development of goods and services
that incorporate, manage and disseminate new technologies, the
low appetite of businesspeople in running such risks continue to
inhibit and wane the participation of the private sector in these
actions. This occurs despite the high S,T&I public policy efforts
enacted along the past two decades.
Regarding the industrial organization, the PNS (Ministry of
Health, 2016, p. 71) sets out three important goals. The first is
to increase from 13 to at least 18 the number of industrial parks
supported by the National Program for the Development of the
Industrial Health Complex (PROCIS). Second, to start at least
4 large partnership projects encompassing research, develop-
ment and innovation (R,D&I) efforts under the new framework
of the PDPs. Third, to implement a Technological Compensa-
tion Agreement (ACT), including the construction of a linear
accelerator industrial facility within the framework of the Radio-
therapy Expansion Plan in the SUS.
In this scenario, some issues still need to be addressed in the
Industrial Organization component. They are as follows:
• How to increase exports and Brazil’s domestic production
in pharmacological and radiopharmaceuticals industries? An
increase of five industrial parks, as highlighted in the PNS
2016–2019, will enable the reversal in the trade balance in
the coming four years?
• How to generate stability and stimulus to pharmacological and
radiopharmaceutical production segments in order to allow
the framework conditions for the competitiveness of these
domestic industries?
• With the R&D productivity drop of the pharmaceutical indus-
try in the world, the country can be an important locus for the
attraction of investments in new of laboratories in the coun-
try, given the lower local R&D overhead costs compared to
developed countries. Having said that, what mechanisms can
be envisioned for such promotion to occur in the best interest
of the improvement in the quality and access to health care
in the country? In addition, how the National Health Program
will allow the construction of a more comprehensive R&D
agenda for the next 4 years?
• The entry of new players in the global market, as the R&D
capacity is globalizing, increases opportunities for competi-
tive companies from emerging economies. What conditions
should be improved and created so that Brazil can become a
prominent player in the segment, given the national research
infrastructure of universities and research centers, along with
major development agencies such as BNDES, FINEP, and
CNPq, among others? What conditions should be improved
for the private sector to increase its interest and participation
in the process of consolidation of a health research agenda in
developing countries like Brazil?
Financial barriers
Financial instruments operated by FINEP and BNDES are
the most representative in fostering S,T&I efforts in the country.
The set of available instruments include reimbursable financing,
non-refundable (sunk-cost) financing and subsidies. Some other
instruments also extend to equity investing like seed and venture
capital, especially from direct public sources or privately man-
aged funds with public funding. The existing funds also assume
the possibility of combining different modes of financing for
Brazilian companies (e.g. reimbursable and sunk-cost funding),
as well as the application for grants to fund cooperative projects
between companies and universities.
In addition to the policy instruments and programs mentioned
earlier, another critical link in the financing of health S,T&I is
played by Brazil’s so called ‘sectoral funds’. FINEP operates
the sectoral funds under the National Scientific and Technologi-
cal Development Fund (FNDCT). The challenges ahead are still
high, given the growing context of resource contention. Cumu-
latively from 1999 to 2015, the retentions in releases of financial
resources from sectoral funds reached R$ 10.7 billion in current
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values. The values released by these funds in the same period
amounted R$ 7.7 billion.1 Having said that, about 58% of bud-
geted resources for sectoral funds were not released to its users
and therefore did not achieve the purposes to which they were
designed.
One of the 15 sectoral funds, the CT-Health, had R$ 703.8
million budgeted for investments in health-related innovation
projects between 2002 and 2015. Only R$ 409.8 million has
reached its beneficiaries. For another health-related fund, CT-
Biotechnology, out of the previously R$ 307.1 million budgeted
for the same period, only a total of R$ 188.4 million has been
released. The resources released so far seem to be still timid to
help the country reach the innovation funding patterns of other
countries. The decline in releases of sector funds between 2014
and 2015 was 69%. For the Health and Biotechnology sectoral
funds, respectively, and at the same period, the funding cuts have
achieved 66% and 87%. By comparison, only the United States,
China and Japan spent half of the $1.6 trillion of global R&D
spending in 2013, nearly a quarter of them in health-related areas
(Battelle, 2013).
Among the other sectoral funds, the one with more direct and
indirect interfaces with the health segments is the CT-Green-
and-yellow (CT Verde e Amarelo), given its interdisciplinary
focus. An assessment of projects funded under the CT-Health,
CT-Biotechnology and projects supported by CT-Green-and-
Yellow with interfaces in health is required since the quality
of the projects supported can also contribute to densify research
and innovation capacities in the health sector.
The challenges for Brazilian funding agencies are significant,
especially in a budget-constrained scenario that may continue in
the coming years. The whereabouts in the global economy may
also contribute to the increased risk in the business model and in
the corporate strategies of the companies supported by Brazilian
public funding sources.
Despite the existing constraints in the country, exports of
aircrafts and the productivity gains achieved in agriculture and
livestock production are good examples of the national techno-
logical performance. The role of government has been important,
but one cannot disregard the role of the private sector with its
capital linked to long-term decisions. Brazil has not yet man-
aged to experience the expected overflow in the intensification
of private R&D efforts translating in a better innovative per-
formance of firms in health-related segments (Cassiolato &
Soares, 2015; Plaza & Santos, 2011). Specificities in the health
segment abound, given its regulatory character by government
authorities, long and costly development cycles, time to market,
complex intellectual property management processes and high
uncertainty in the continuity of their technological paths (Lange
et al., 2013; Lehoux et al., 2014).
As a segment of intrinsic complexity, there are important
gaps in the nature of private funding in the health sector in the
1 The data presented in this Section was collected by the authors from
the Ministry of Science, Technology and Innovation website. Available in
<http://www.mct.gov.br/index.php/content/view/725.html>. Accessed on 14
October 2016.
country, particularly with regard to high-tech enterprises. This
aspect deserves further investigation, as it implies conditions that
can unnecessarily translate into even greater opportunity costs to
the private investors, thereby affecting their resource allocation
decisions for investments in new projects in the area of health.
In fact, when looking at data from the Brazilian Private Equity
and Venture Capital Association (ABVCAP), one observes that
private equity investments in health-related sectors have been
declining since 2011, while others grew – despite the adverse
economic scenario prevailing in the country (Brazilian Private
Equity and Venture Capital Association, 2016). As we withdraw
the recent acquisitions of equity in private hospitals by national
and foreign private equity funds operating in the country, the
data are even more worrisome, given the importance of this type
of investment to innovation (Metrick & Yasuda, 2011).
The PNS from 2016 to 2019 is generalist when presenting its
plans to reduce the financial barriers underpinning more coher-
ent and functional health innovations in Brazil. The goals set out
by the PNS in regard are as follows (Ministry of Health, 2016, p.
84): (1) to agree on new criteria for apportionment of resources
among the federal entities starting from each federative unit’s
health responsibilities; (2) to establish new modes of resource
transfer, inducing full care lines for access to health specializa-
tions; and (3) to reduce, on an annual basis, the average price of
contractual acquisitions based on PDPs.
Due to the still existing financial barriers for health inno-
vation, we propose the following set of questions on this
component:
• With the escalating development costs and increased regu-
latory risks, particularly in the development of drugs, what
actions can be envisaged to reduce these costs and risks and
to increase private investment, domestic and foreign, in the
country?
• With high constraints on public spending, how to encourage
the private sector to participate more actively? What benefits
should be offered to domestic and foreign agents to invest in
the various links of the CEIS in the country?
• How functionally to fill in the gaps in the funding side, for
example, for the so-called ‘valley of death’ (development time
gap between scientific discovery and the authorization for
clinical testing in humans), in the funding for translational
research, as well as for the gaps in the funding available
for disease/clinical approaches of lower commercial interest,
etc.?
• How can the attractiveness of domestic companies be
improved to investors, so that they can understand the syn-
ergies and value proposition of these enterprises, given the
need for further efforts to improve the valuation of assets and
companies based on the knowledge they possess?
Final remarks
The low rate and intermittent development of government
programs and markets encouraged by governmental actions
made that so far the economic, financial and social benefits
resulting from the opportunities generated had little impact in
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terms of reducing the gap between health R&D and innovation in
the country. This was due to factors ranging from the complex-
ities involved in scaling up to the governance issues of various
institutions and public bodies, including budgetary instability, in
combination with the absence of monitoring and evaluation of
specific policies and their consequent reformulations and refine-
ments. However, if public policies were not yet sufficient to
enable a densification of a national HIS, as proposed by CEIS,
they have been providing an important extended life for hospi-
tals, research centers, suppliers and users of health goods and
services to accumulate experience in human resource qualifica-
tion and in the improvement of R&D processes in such a manner
to reduce in the future their dependency on public resources.
In view of the set of considerations elaborated in this research
paper, it remains urgent to consolidate and expand the efforts
for building a research agenda strictly focused on the resolu-
tion of restrictions arising from health innovation gaps in the
country. Both in the national and international contexts, such
agenda ought to consider an extension of the policy scope and
respective strategies for monitoring and evaluation of results
of the experiments of other countries like Germany, China,
France, India, Israel, Switzerland, United States and Japan, as
well as in-depth studies of specific ecosystems, institutional
arrangements and incentive patterns in selected international
programs.
Next, one must establish, from the in-depth analysis of these
experiences and of the most recent studies, a comparative assess-
ment of the performance of the Brazilian health innovation
policy. This is a necessary component for the strengthening
of the constraints of a more competitive CEIS, which reflects
the specific links of the Brazilian reality. Third, and in a
complementary and concomitant manner, one must establish a
multi-institutional research program on indicators and metrics
for monitoring and evaluation of health innovation. Finally, one
must prioritize the following elements: (i) a mapping and an in
depth-analysis of aspects and components identified as critical
of health innovation ecosystems, which affect the organization
of the health science and technology system; (ii) a study of the
evolutionary conditions of governance and of the dynamics of
institutional arrangements of Brazilian health innovation policy,
which affects the organization of the industry; and (iii) a critical
analysis of its current incentive patterns, both public and private,
which affect the funding mechanisms.
Such considerations engender a set of measures aimed at a
more coordinated, coherent and continuous promotion of CEIS
in regards to a competitive international insertion of the national
productive base, an improvement of public and private funding
institutions and a university–industry relationship more oriented
to technological innovation in strategic areas for health in the
country. In addition, but not less important, to policy improve-
ment in areas that, even indirectly, affect the quality of domestic
services and products provision in pharmaceuticals, inputs and
medical equipment.
The Brazilian CEIS, therefore, must incorporate the concerns
brought about by aspects of the internationalized science and
technology base, of the competitive organization of industry and
of the growing shortage of financial resources, to make more
efficient the complex process from research to the development
of new health technologies and their subsequent dissemination in
medical practice, particularly under the SUS, so as to reflect the
picture of health and disease of the population with its regional
specificities and needs. It is not, as is known, a linear process
with beginning, middle and end; but rather a cycle with creation
and evolution of complex connections between the agents, typi-
cal of a ‘behavioral ecology’ partly shaped by incentive systems
established by institutions, including the market, and public and
private organizations, which produces the basis for an institu-
tionally more mature and evolutionary CEIS, thus with efficacy
and sustainable.
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